Literature DB >> 31938221

125I inhibited the NSCLC both in vivo and in vitro.

Weiliang Yan1, Xiaodong Huo2, Huixing Wang3, Bin Huo2, Yongtao Guo4, Hua Dong4, Guangjun Zheng1, Junjie Wang5, Shude Chai1, Haitao Wang2, Zuncheng Zhang4.   

Abstract

Lung cancer is the main reason of cancer-linked death all over the world. Non-small cell lung cancer (NSCLC) patients always have an extremely poor prognosis. It is urgent to find novel treating methods. It was previously showed that 125I brachytherapy had been applied to the lung cancer treatment. However, fundamental researches are limited. In the present study, we first explored the mechanism by which 125I radiation induced arrest or apoptosis of the cell cycle and relevant protein expression. Furthermore, we explored its effect on the invasion. We found that 125I significantly induced cell apoptosis through mitochondrial pathway, triggered S phase arrest via regulating cyclinA2, p21 and CDK6 expressions. Meanwhile, 125I could inhibit invasion of NSCLC cells by altering the expression level of vimentin, N-cadherin and MMP-9. Furthermore, we confirmed the effects of 125I on NSCLC cell growth in vivo. The results indicated that 125I obviously inhibited the tumor growth. Thus, we determined that 125I brachytherapy remarkably restrained NSCLC cellular growth and intrusion by inducing apoptosis, S phase arrest and corresponding protein expression. IJCEP
Copyright © 2018.

Entities:  

Keywords:  125I; NSCLC; apoptosis; radioresistance

Year:  2018        PMID: 31938221      PMCID: PMC6958116     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  13 in total

1.  Prognostic factors for long term survival in patients with advanced non-small cell lung cancer.

Authors:  Despoina Moumtzi; Sofia Lampaki; Paul Zarogoulidis; Konstantinos Porpodis; Kalliopi Lagoudi; Wolfgang Hohenforst-Schmidt; Athanasia Pataka; Theodora Tsiouda; Athanasios Zissimopoulos; George Lazaridis; Vasilis Karavasilis; Helen Timotheadou; Nikolaos Barbetakis; Pavlos Pavlidis; Theodoros Kontakiotis; Konstantinos Zarogoulidis
Journal:  Ann Transl Med       Date:  2016-05

2.  [The technique of stereotactic I125 brachytherapy (permanent implants) of brain tumors in Vienna].

Authors:  R Hawliczek; P Grunert; H Ferraz-Leite; F Alesch
Journal:  Strahlenther Onkol       Date:  1990-10       Impact factor: 3.621

3.  Iodine-125 brachytherapy improved overall survival of patients with inoperable stage III/IV non-small cell lung cancer versus the conventional radiotherapy.

Authors:  Wei Li; Jing Guan; Lie Yang; Xiushan Zheng; Yongkang Yu; Jianqing Jiang
Journal:  Med Oncol       Date:  2014-11-27       Impact factor: 3.064

4.  Dosimetric and technical aspects of intraoperative I-125 brachytherapy for stage I non-small cell lung cancer.

Authors:  Mark Johnson; Athanasios Colonias; David Parda; Mark Trombetta; Olivier Gayou; Bodo Reitz; Moyed Miften
Journal:  Phys Med Biol       Date:  2007-01-31       Impact factor: 3.609

5.  Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer.

Authors:  Ricardo Santos; Athanasios Colonias; David Parda; Mark Trombetta; Richard H Maley; Robin Macherey; Susan Bartley; Tibetha Santucci; Robert J Keenan; Rodney J Landreneau
Journal:  Surgery       Date:  2003-10       Impact factor: 3.982

6.  A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.

Authors:  David Planchard; Takashi Yokoi; Michael J McCleod; Jürgen R Fischer; Young-Chul Kim; Marc Ballas; Kelvin Shi; Jean-Charles Soria
Journal:  Clin Lung Cancer       Date:  2016-03-17       Impact factor: 4.785

7.  Investigating CTCs in NSCLC-a reaction to the study of Jia-Wei Wan: a preliminary study on the relationship between circulating tumor cells count and clinical features in patients with non-small cell lung cancer.

Authors:  Menno Tamminga; Hendricus Harry Johannes Marie Groen; Thijo Jeroen Nicolaas Hiltermann
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

8.  Survival impact of locoregional metachronous malignancy in survival of lung cancer patients who received curative treatment.

Authors:  Chi-Tsung Wen; Jui-Ying Fu; Ching-Feng Wu; Ming-Ju Hsieh; Yun-Hen Liu; Yi-Cheng Wu; Ying-Huang Tsai; Ching-Yang Wu
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

9.  Iodine125 interstitial brachytherapy in the treatment of carcinoma of the lung.

Authors:  E H Fleischman; A R Kagan; O E Streeter; J Tyrell; M Wollin; C A Leagre; J C Harvey
Journal:  J Surg Oncol       Date:  1992-01       Impact factor: 3.454

10.  CT-guided radioactive seed implantation for recurrent rectal carcinoma after multiple therapy.

Authors:  Jun Jie Wang; Hui Shu Yuan; Jin Na Li; Yu Liang Jiang; Su Qing Tian; Rui Jie Yang
Journal:  Med Oncol       Date:  2009-05-05       Impact factor: 3.064

View more
  1 in total

1.  Epirubicin Enhances the Anti-Cancer Effects of Radioactive 125I Seeds in Hepatocellular Carcinoma via Downregulation of the JAK/STAT1 Pathway.

Authors:  Lei Guo; Jiali Sun; Changjun Wang; Yang Wang; Ya Wang; Dong Li; Yuliang Li
Journal:  Front Oncol       Date:  2022-05-27       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.